Leonardo BioSystems Inc. uses proprietary multi-stage nanovector drug delivery technology to facilitate chemotherapy and biological anti-cancer agent delivery. Leonardo’s drug delivery approach is focused on overcoming biological barriers such as renal clearance, the blood-brain barrier, serum proteases, nucleases, endothelial capillary lining, and the reticuloendothelial system. Such bio-barriers have traditionally thwarted advanced nanoparticle delivery products and have limited the progress of nanoparticle delivery strategies. The ability to effectively deliver pharmaceuticals by overcoming bio-barriers generates significant benefits in the form of new treatments for disease, new uses of old treatments, and enabling the field of nanoparticle drug delivery. The Company’s first target market is drug refractory breast cancer. [ read more ]

Nanotope is a regenerative medicine company that leverages a set of core platform technologies to address multiple therapeutic markets. It is built around technology developed by Professor Samuel Stupp, Director of the Institute for BioNanotechnology in Medicine at Northwestern University. Nanotope is developing a suite of products, each customized to regenerate specific tissues; including neuronal, vascular, bone, myocardial, and cartilage. The products are injectable compounds that work with surviving cells in and around the point of injury to initiate and support regeneration where it would not naturally occur or to speed recovery. Once regeneration is complete, the compounds are safely broken down and removed by the body. Nanotope’s lead products target (a) spinal cord regeneration for the reversal of paralysis associated with spinal cord injury and (b) angiogenesis for advanced wound healing and the treatment of peripheral artery disease.